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MethMarker <p>A software workflow to translate known differentially methylated regions into clinical biomarkers</p>
Abstract
DNA methylation is a key mechanism of epigenetic regulation that is frequently altered in diseases
such as cancer. To confirm the biological or clinical relevance of such changes, gene-specific DNA
methylation changes need to be validated in multiple samples. We have developed the MethMarker
http://methmarker.mpi-inf.mpg.de/ software to help design robust and cost-efficient DNA
methylation assays for six widely used methods. Furthermore, MethMarker implements a
bioinformatic workflow for transforming disease-specific differentially methylated genomic regions
into robust clinical biomarkers.
Rationale
Aberrant DNA methylation is a common event in many can-
cers [1,2]. Functionally, cancer-specific hypermethylation
imposes condensed chromatin structure upon CpG islands
that normally exhibit an open and transcriptionally compe-
tent chromatin structure [3]. This epigenetic alteration
results in loss of expression at nearby genes, contributing to
cancer development when tumor suppressor genes are
affected [4].
For many years, research in cancer epigenetics has focused on
the use of CpG island hypermethylation events of certain
genes as cancer biomarkers, with the aim of improving cancer
treatment through more accurate diagnosis, prognosis and
therapy selection [5,6]. Early diagnosis exploits the fact that
CpG island hypermethylation of cancer-related genes is fre-
quently detectable in early-stage tumors [7], for which surgi-
cal treatment can be highly effective. Prognosis of clinical
outcome uses DNA hypermethylation events to infer whether
or not a tumor is likely to constitute a major threat to the
patient's health, which is particularly relevant for cancers that
will kill only a subset of patients if left untreated (for example,
prostate cancer). Therapy optimization makes use of DNA
methylation differences between patient subgroups in order
to select the most effective treatment, thus contributing to
personalized cancer treatment.
In spite of significant investment in genome-wide screening
and subsequent validation studies, few DNA methylation
biomarkers have been confirmed by clinical trials. This bot-
tleneck in the process of translating basic research findings
into the clinic is partially due to a discontinuity of methods
between the discovery phase and the validation phase. The
methods used most commonly in the discovery phase (such as
tiling microarray and clonal bisulfite sequencing) are too
time-consuming and expensive to be used in the clinical set-
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ting. Hence, candidate biomarkers have to be adapted to high
sample-throughput methods such as MethyLight [8],
bisulfite pyrosequencing [9-11], COBRA (combined bisulfite
restriction analysis) [12] or bisulfite single nucleotide primer
extension (SNuPE) [13,14]. To be effective, this adaptation
step requires substantial bioinformatic optimization and val-
idation.
Based on our experience from a pilot study on the O6-methyl-
guanine DNA methyltransferase (MGMT) gene [15], we have
developed a systematic workflow for design, optimization and
validation of DNA methylation biomarkers (reviewed in [16]).
The six-step procedure outlined in Figure 1 starts from a
preselected differentially methylated region (DMR), which
may have been identified by genome-wide screening experi-
ments or through a candidate gene approach. A typical exam-
ple would be a CpG island that overlaps with the promoter
region of a tumor suppressor gene. In the first step, this
region is subjected to high-resolution analysis of DNA meth-
ylation in a small number of cases and controls (for example,
by clonal bisulfite sequencing). These experimental data pro-
vide MethMarker with a representative map of methylation
state within the DMR and inform all subsequent optimization
steps. Second, using sets of expert rules, technically feasible
DNA methylation assays are designed for each of six robust
and cost-efficient experimental protocols (COBRA, bisulfite
SNuPE, bisulfite pyrosequencing, MethyLight, methylation-
specific polymerase chain reaction (MSP) and methylated
DNA immunoprecipitation quantitative PCR (MeDIP-
qPCR)). Third, the accuracy of all designed assays is compu-
tationally assessed, using the DNA methylation map derived
in the first step. Fourth, the most promising candidate
biomarkers are statistically optimized for maximum discrim-
ination between cases and controls. Fifth, to reduce the risk
that candidate biomarkers subsequently fail due to technical
problems or lack of robustness, all high-scoring assays are
validated with respect to their susceptibility to experimental
noise, measurement errors and unknown single nucleotide
polymorphisms. Sixth, the most promising assay is selected,
experimentally tested and further optimized based on the
outcome of the experimental validation. After completion of
these six steps, the candidate biomarker is ready for applica-
tion and further validation in clinical studies.
Apart from two key experimental analyses - the generation of
high-resolution DNA methylation data in step one and assay
validation in step six - this workflow is essentially bioinfor-
matic in nature. We developed the MethMarker software as a
user-friendly implementation of the bioinformatic steps,
including automatic assay design for six widely used experi-
mental methods (COBRA, bisulfite SNuPE, bisulfite pyrose-
quencing, MethyLight, MSP and MeDIP-qPCR) and
computational biomarker optimization. MethMarker inte-
grates well with existing bioinformatic tools for analyzing
DNA methylation (reviewed in [17]): epigenome analysis
tools such as Galaxy [18] and EpiGRAPH [19] can be used to
select promising DMRs for optimization with MethMarker,
and high-resolution DNA methylation data can be imported
directly from three widely used software packages, BiQ Ana-
lyzer [20], QUMA [21] and EpiTYPER [22], as well as from
custom tables. Finally, optimized biomarkers can be exported
in the standardized predictive model markup language
(PMML) format [23], which facilitates interoperation with
molecular diagnostics software. A typical screenshot of Meth-
Marker is displayed in Figure 2.
Application
To illustrate the biomarker development workflow outlined
in Figure 1 and to demonstrate the practical use of Meth-
Marker, we describe its application to the MGMT gene pro-
moter, highlighting important decisions, necessary validation
experiments and potential stumbling blocks. The raw data for
MethMarker employs a six-step workflow to design, optimize and validate  DNA methylation biomarkers for a given differentially methylated DNA  region (DMR) Figure 1
MethMarker employs a six-step workflow to design, optimize 
and validate DNA methylation biomarkers for a given 
differentially methylated DNA region (DMR). In addition to its main 
purpose as a full-scale biomarker development tool, MethMarker can also 
be used simply as an assay design software, in which case steps 3 to 6 
(yellow boxes) are omitted.
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this case study are taken from a recent experimental study
[15] and are included as a demonstration dataset in the Meth-
Marker download package.
The  MGMT  gene encodes a DNA repair protein, which
removes alkyl groups from the O6-position of guanine, there-
fore protecting the DNA from accumulating excessive damage
[24]. It has been shown in a number of studies (see [25] and
references therein) that hypermethylation of the MGMT pro-
moter is a frequent event in various cancers (that is, is rele-
vant for diagnosis), that it is associated with decreased
survival if the cancer is untreated (that is, is relevant for prog-
nosis), and that it renders tumors susceptible to alkylating
drugs such as temozolomide (that is, is also relevant for ther-
apy optimization). However, until recently no assay for meas-
uring MGMT promoter methylation had been available that
was robust enough for routine clinical use and fully compati-
ble with DNA extracted from formalin-fixed, paraffin-embed-
ded samples [26].
For these reasons, the promoter of the MGMT gene is an
excellent target region for demonstrating the systematic
development of a DNA methylation biomarker, such that the
resulting assay is accurate, robust and cost-efficient enough
for clinical use. To start with, we obtain the genomic DNA
sequence of the MGMT  promoter region from the UCSC
Genome Browser [27]. We also obtain 22 glioblastoma sam-
ples, a subset of them showing MGMT promoter methylation,
as well as three normal brain samples for use as healthy tissue
controls. Next, bisulfite-specific PCR primers are designed
(manually or using a software tool such as Methyl Primer
Express [28]), and clonal bisulfite sequencing is performed
on DNA from all samples according to a widely used protocol
[29]. The sequencing data are processed and quality control-
led with BiQ Analyzer [20], resulting in 25 high-resolution
DNA methylation profiles that are used as training samples.
(Note that it is usually sufficient to have five to ten training
samples per class to guide the optimization step. In our case,
however, it was not clear a priori how many of the tumor
This figure shows a screenshot of MethMarker's main analysis window Figure 2
This figure shows a screenshot of MethMarker's main analysis window. From top to bottom, MethMarker displays gene annotation data for the 
region of interest; its genomic DNA sequence as well as the bisulfite converted sequence; automatically generated assays for the supported experimental 
methods (COBRA, bisulfite SNuPE, bisulfite pyrosequencing, MSP, MethyLight and MeDIP-qPCR); DNA methylation information for the region of interest, 
which has been loaded into MethMarker (yellow bars correspond to unmethylated CpGs, blue bars to methylated CpGs); a statistical summary of CpG 
positions within the region of interest; and - at the bottom - a text field providing advice for the user. All views are highly interactive and can be adjusted 
to control MethMarker's behavior.http://genomebiology.com/2009/10/10/R105 Genome Biology 2009,     Volume 10, Issue 10, Article R105       Schüffler et al. R105.4
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samples would turn out to belong to the methylated cases or
to the unmethylated controls, respectively. Hence, a relatively
large number of samples were subjected to clonal bisulfite
sequencing.)
Next, the genome sequence of the target region, the corre-
sponding primer sequences and the BiQ-Analyzer processed
DNA methylation profiles are imported into MethMarker.
The software tool automatically identifies the correct location
of the MGMT promoter on human chromosome 10, visualizes
the position of the first exon and aligns the DNA methylation
profiles of all 25 training samples (Figure 2). We let Meth-
Marker classify the training samples into cases and controls,
using hierarchical clustering of the DNA methylation profiles.
Consistent with previous observations, we obtain a large clus-
ter of samples in which the MGMT promoter is unmethylated
and a smaller cluster consisting of tumor samples with meth-
ylated MGMT promoters. The former cluster - which we will
refer to as 'controls' - contains the normal brain samples and
a subset of tumors that are likely to be resistant to alkylating
agents used for chemotherapy. The latter cluster ('cases')
comprises tumor samples only, presumably those that are
susceptible for chemotherapy using alkylating drugs such as
temozolomide [30].
Based on this classification, our goal is to find a DNA methyl-
ation assay (or a combination of several assays) that provides
accurate, robust and cost-efficient separation between cases
and controls. First, we let MethMarker design all feasible
DNA methylation assays for the target region, using COBRA,
bisulfite SNuPE, bisulfite pyrosequencing, MethyLight and
MeDIP-qPCR. We chose to exclude MSP because several
MSP-based assays for MGMT  promoter hypermethylation
are already available [26] and because MSP-based assays do
not always work well on formalin-fixed, paraffin-embedded
samples [15]. Next, we let MethMarker score the individual
assays in terms of their correlation with the overall DNA
methylation level in each of the training samples (Additional
data file 1). A Pearson correlation coefficient above 0.9 and a
Spearman correlation coefficient above 0.8 indicate a highly
accurate and predictive assay. Even when a single CpG site
already provides a highly accurate measurement - as is the
case here - it is highly recommended to use a combination of
at least three to four CpG sites in order to increase robustness
of the DNA methylation assay in the presence of experimental
noise and rare sequence polymorphisms. To that end, Meth-
Marker identifies the optimal combinations of DNA methyla-
tion assays for each method, again ranked by their correlation
with the overall DNA methylation level in each of the training
samples (Additional data file 1).
From the resulting list, we select several assay combinations
that appear to provide a suitable balance between accuracy,
robustness and cost (higher robustness is usually achieved by
including more CpG sites, which makes the candidate
biomarker more expensive to use). For each of these assay
combinations, we let MethMarker optimize logistic regres-
sion models that predict whether a sample belongs to the
cases or to the controls (Figure 3). During this step, weights
are learned for the individual assays in order to maximize the
classification accuracy of the candidate biomarker. Meth-
Marker benchmarks the candidate biomarkers in terms of
accuracy, correlation, specificity and sensitivity. Additionally,
the biomarkers' robustness is assessed by comparing false
positive and false negative rates under increasing error rate,
by simulating noisy measurement data. This step accounts for
the fact that not all error sources may be well-represented in
the training data. For example, COBRA, bisulfite SNuPE and
bisulfite pyrosequencing are sensitive to rare inherited C-to-
T single nucleotide polymorphisms at the assayed CpGs, and
MSP as well as MethyLight can give rise to erroneous meas-
urements if the DNA methylation profile in the target region
only partially matches with the designed probe (see Mikeska
et al. [15] and Bock et al. [20] for a more in-depth discussion
of potential error sources).
For each candidate biomarker, MethMarker also calculates
an extensive performance evaluation summary (Figure 4).
We use the results from this window to compare how well sev-
eral top-scoring candidate biomarkers separate between the
methylated cases and unmethylated controls. Also, we test
the robustness of each candidate biomarker by artificially
introducing noise and observing how much noise it can toler-
ate until the first classification errors start to appear. As a
quintessence of all performance evaluations of MethMarker,
we conclude that the following two candidate biomarkers are
most suitable for assessing promoter hypermethylation of the
MGMT gene in routine clinical use: the COBRA biomarker
comprising CpG sites 5/6 and 18, utilizing the Hpy99I and
HpyCH4III restriction endonucleases (r = 0.985), and the
bisulfite pyrosequencing biomarker comprising CpG sites 13,
18 and 20 (r = 0.990). Both biomarkers achieve 100% test set
accuracy during leave-one-out cross-validation. Compared to
the biomarkers that we previously established for the same
dataset [15], the biomarkers identified by MethMarker
achieve an identical accuracy and score marginally higher in
terms of correlation and robustness (data not shown). Never-
theless, we recommend that practical studies of MGMT pro-
moter methylation continue using the previously published
biomarkers [15] because they have been validated experimen-
tally, while the two MethMarker-derived biomarkers
reported here have not been tested on clinical samples.
Having completed the design, optimization and computa-
tional validation of candidate biomarker DNA methylation
assay for the MGMT promoter, two key steps remain: experi-
mental assay validation and experimental biomarker valida-
tion. First, it is essential to make sure that the DNA
methylation assays included in the selected biomarker work
well in the lab and result in roughly the same DNA methyla-
tion measurements as predicted based on the high-resolution
DNA methylation profiles. To that end, the assays are appliedhttp://genomebiology.com/2009/10/10/R105 Genome Biology 2009,     Volume 10, Issue 10, Article R105       Schüffler et al. R105.5
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to DNA from the training samples, and each assay's empirical
measurement value is compared with the simulated measure-
ment value that MethMarker calculated from the high-resolu-
tion profiles. Assays showing low correlation or high
deviation should be rejected from practical use as biomark-
ers. Second, the most important step for any new DNA meth-
ylation biomarker is to validate its sensitivity, specificity and
practical utility in a large number of patients, both by retro-
spective studies based on archival material with known clini-
cal history and in prospective clinical trials. While several
clinical trials have already confirmed the effect of MGMT
hypermethylation on chemotherapy resistance in gliomas
[31] and glioblastomas [30,32], the MethMarker-optimized
biomarker may facilitate the clinical confirmation of MGMT's
predictive role in other cancers.
Conclusions
Recent advances in genome-wide DNA methylation mapping
have provided researchers with rapid and cost-efficient ways
to contribute to the ever-growing list of genomic regions
reported as differentially methylated in specific cancers and/
or patient subgroups. However, a comparable advance for the
efficient conversion of DMRs into clinical biomarkers is lack-
ing. Thus, the rate with which new DNA methylation biomar-
kers are tested and confirmed in clinical trials has remained
disappointingly low. While it is inevitable that a large per-
centage of candidate biomarkers will fail in clinical trials
(either because they are not reproducible in different patient
cohorts or because their sensitivity and specificity are insuffi-
cient for practical use), a more systematic approach to epige-
netic biomarker development could help discard many of
This figure displays a screenshot of MethMarker's biomarker performance comparison, assessing the robustness of candidate biomarkers to elevated error  rates Figure 3
This figure displays a screenshot of MethMarker's biomarker performance comparison, assessing the robustness of candidate 
biomarkers to elevated error rates. In this example, CO_30 and CO_16 exhibit the overall best performance, in terms of low false positive/negative 
rates as well as high levels of accuracy, sensitivity, specificity and correlation.http://genomebiology.com/2009/10/10/R105 Genome Biology 2009,     Volume 10, Issue 10, Article R105       Schüffler et al. R105.6
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these unsuccessful candidates early and at low cost. Con-
versely, careful selection and optimization of candidate
biomarkers can reduce the risk of losing effective biomarkers
due to contingencies of the validation process, such as acci-
dental selection of DNA methylation assays that measure
highly noisy CpG positions in a promoter region that would
otherwise provide reliable classification. The workflow
described in this paper provides a starting point toward a
more systematic way of transforming disease-specific DMRs
into robust and cost-efficient clinical biomarkers. The Meth-
Marker software was developed to facilitate the implementa-
tion of this workflow. To enable further refinement and
adaptation to local requirements, we are happy to share
MethMarker's source code with interested researchers.
Materials and methods
MethMarker is implemented in Java (version 1.5 or later
required). It is platform-independent and can be launched
directly from within a web browser. The software comes with
a case-study tutorial demonstrating the design, optimization
and validation of a DNA methylation biomarker based on the
A screenshot of MethMarker's performance window, summarizing the evaluation of a bisulfite pyrosequencing-based biomarker Figure 4
A screenshot of MethMarker's performance window, summarizing the evaluation of a bisulfite pyrosequencing-based biomarker. In the 
upper panel, MethMarker displays the optimized regression formula, which predicts - based on measurement values for CpGs number 5 and 18 - whether 
a sample belongs to the case (that is, is methylated, indicated by positive score values) or to the control group (that is, is unmethylated, indicated by 
negative score values). Note that the score value is a measure of the probability with which the sample is a case rather than a control, not an estimate of 
the DNA methylation level (in fact, the probability p can be calculated from the score s with a simple formula:  . The center panel displays the 
results of leave-one-out cross-validation, providing an estimate of the biomarker performance on new data. The diagrams at the bottom visualize the 
degree of separation between the two classes when plotting the measured level of DNA methylation over the score value of the regression formula (left) 
and the robustness of predictions in the face of increasing noise levels (right).
p
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MGMT gene. MethMarker's user interface reflects the work-
flow for biomarker design, optimization and validation out-
lined in Figure 1.
Step 1: data import
As the first step, the DMR of interest is imported. Meth-
Marker supports several sequence formats, including FASTA,
GenBank and EMBL. Typical regions of interest include the
promoters of tumor suppressor genes and CpG islands that
exhibit cancer-specific hypermethylation. However, Meth-
Marker imposes no restrictions on the type of region to be
analyzed. MethMarker can thus be applied not only to human
cancers, but more generally to epigenotyping in all kinds of
organisms that exhibit CpG dinucleotide methylation.
High-resolution DNA methylation profiles for a subset of
cases and controls are crucial for MethMarker's optimization
process, as they provide the training set on which all candi-
date biomarkers are optimized and computationally vali-
dated. These profiles are usually derived by clonal bisulfite
sequencing [33] or mass spectrometry and preprocessed with
appropriate tools. MethMarker can directly import DNA
methylation profiles from files generated with BiQ Analyzer
[20], QUMA [21] and EpiTYPER [22], and it is easy to convert
DNA methylation data from a different source into a format
that can be read by MethMarker.
On completion of data import, MethMarker displays a high-
resolution DNA methylation profile of the region of interest,
visualized as lollipop diagrams or as methylation propensity
diagrams. Internally, MethMarker uses Needleman-Wunsch
sequence alignment [34] in order to correct for incomplete
overlap between the target region and the DNA methylation
profiles. It is thus possible to tile a large target region with
several bisulfite sequencing amplicons.
Optionally, MethMarker can annotate the region with tran-
scription start site and exon positions retrieved from the
UCSC Genome Browser [27]. To that end, MethMarker per-
forms an automatic BLAT search on the UCSC Genome
Browser website, obtains the genomic coordinates of the
region and retrieves exon information for overlapping Ref-
Gene genes from the UCSC Table Browser. Data on single
nucleotide polymorphisms are acquired in the same way, ena-
bling MethMarker to avoid polymorphic sites when designing
DNA methylation assays. All annotation data can be manually
revised and amended.
Step 2: design of DNA methylation assays
MethMarker implements automatic assay design for six
experimental methods commonly used for DNA methylation
analysis: COBRA, bisulfite SNuPE, bisulfite pyrosequencing,
MethyLight, MSP and MeDIP-qPCR. The first five methods
utilize bisulfite treatment of genomic DNA to detect DNA
methylation indirectly. However, they differ in the way they
interrogate the amount of DNA methylation, leading to spe-
cific experimental constraints that limit the application of
each method to assaying a subset of CpG positions. The sixth
method, MeDIP-qPCR, uses an antibody-based approach to
enrich for methylated genomic DNA, which leads to quite dif-
ferent experimental constraints [35]. For all methods, assay
design rules were developed, reviewed by domain experts and
implemented in MethMarker, as described in more detail in
the MethMarker assay design dialogue. However, it is recom-
mended that all primers designed with MethMarker are
reviewed by the experimenter before ordering, to exclude
problems such as hairpins, self-dimers and cross-dimers,
which MethMarker does not automatically check for.
All automatically designed DNA methylation assays can be
visualized, revised or excluded by the user, for example, based
on results of previous experiments. Furthermore, Meth-
Marker allows users to define and incorporate custom assays,
which enables the software to include experimental methods
that are not directly supported.
Step 3: scoring of DNA methylation assays
Based on the samples for which high-resolution DNA methyl-
ation profiles are available (see step 1), MethMarker scores all
DNA methylation assays in terms of their correlation with the
overall level of DNA methylation in each sample. The meas-
urement values of the DNA methylation assays are calculated
directly from the high-resolution DNA methylation profiles,
using a set of method-specific rules. For COBRA, bisulfite
SNuPE and bisulfite pyrosequencing, the measurement value
is calculated simply as the average DNA methylation level of
the assayed CpG site(s), based on the high-resolution DNA
methylation profiles of the respective sample. For MSP,
MethyLight and MeDIP-qPCR, the measurement value is cal-
culated as the percentage of individual clones in which all par-
ticipating CpG sites are simultaneously methylated. To better
resemble real PCR conditions, for MSP and MethyLight a sin-
gle CpG position is allowed to have an incorrect methylation
value. While simulated measurements cannot replace experi-
mental validation of the resulting DNA methylation assays
(see [36] for a discussion of the limitations of simulating DNA
methylation measurements in silico), they provide a suitable
indication for identifying the most predictive DNA methyla-
tion assays to be included in the optimization step.
Step 4: biomarker optimization
From the list of DNA methylation assays, ranked by their cor-
relation with the overall DNA methylation levels of the train-
ing samples, the user can select a subset for biomarker
optimization. MethMarker then scores all possible combina-
tions of the selected DNA methylation assays and again
assesses the correlation with the overall DNA methylation
levels of the training samples. To allow for fair comparison
between assay sets of different sizes, no weight fitting is per-
formed at this stage. Rather, the score value of each combina-
tion is calculated as the mean measurement value of all
contributing DNA methylation assays. The results of thishttp://genomebiology.com/2009/10/10/R105 Genome Biology 2009,     Volume 10, Issue 10, Article R105       Schüffler et al. R105.8
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comparison are listed in the order of decreasing correlation
coefficients, and the user can select a subset of the most
highly scoring combinations of DNA methylation assays for
optimization and computational validation as candidate
biomarkers, a procedure that is performed as follows.
First, the training samples are classified into cases and con-
trols. This classification can be performed based on known
sample information (for example, tumor samples versus nor-
mal tissue annotation) or based on the DNA methylation pro-
files themselves, using one of the following methods: a fixed
threshold on the average DNA methylation level, hierarchical
clustering, or K-means clustering with K = 2. In all cases, the
DNA methylation profiles in the subset with the higher aver-
age methylation levels are labeled as methylated 'cases' and
the remaining profiles are labeled as unmethylated 'controls'.
Second, logistic regression is used to optimize the weight with
which the individual measurements contribute to the overall
biomarker score, accounting for the fact that different CpGs
vary in their predictiveness of the overall level of DNA meth-
ylation. Internally, MethMarker uses the WEKA package [37]
to train a logistic regression model for each candidate
biomarker, classifying the training samples into cases versus
controls based on simulated methylation measurements for
all contributing CpGs.
Third, the predictiveness of the logistic regression models is
validated by leave-one-out cross-validation - that is, the logis-
tic regression models are repeatedly trained on all but one
training samples and their prediction performance is
assessed on the remaining sample. The results of the optimi-
zation step, including a cross-validation-based estimate of the
prediction performance on new data, are displayed in the
biomarker summary window (Figure 4).
Step 5: validation of DNA methylation biomarkers
While the results of the leave-one-out cross-validation (step
4) already provide an important selection criterion for identi-
fying the most suitable DNA methylation biomarkers, they do
not account for potential errors and experimental problems
that can occur during practical use. MethMarker therefore
provides an additional validation step, which assesses the
robustness of each candidate biomarker toward noisy data,
sequencing errors and unknown single nucleotide polymor-
phisms. In this step, the optimal logistic regression model is
re-applied to all samples for which high-resolution DNA
methylation profiles are available (this can include samples
that were not taken into account in the training phase - for
example, because they constitute outliers or borderline
cases), and the biomarker's prediction confidence for a given
sample is plotted against its mean DNA methylation level, as
calculated from the DNA methylation profiles. It is thus pos-
sible to visually assess how well each candidate biomarker
separates between the (methylated) cases and (unmethyl-
ated) controls. Furthermore, MethMarker assesses the
robustness toward erroneous data - such as sequencing errors
or unknown single nucleotide polymorphisms - by randomly
changing the DNA methylation measurement of a subset of
CpGs. The error rate is varied over a wide range, and the
impact on the prediction accuracy is visualized in the biomar-
ker summary window (Figure 4), enabling the user to assess
whether or not a specific candidate biomarker is sufficiently
robust for clinical use.
Step 6: application of DNA methylation biomarkers
Based on the results of the computational assessment, the
user selects a few of the most promising biomarkers for
experimental validation, performs the necessary DNA meth-
ylation assays on DNA from the training samples and uploads
the results into MethMarker. By comparison between the
simulated and actual measurements, MethMarker can evalu-
ate the reliability of each candidate biomarker under routine
experimental conditions and re-train its logistic regression
models accordingly (for example, down-weighting the contri-
bution of a CpG whose DNA methylation assay exhibits a high
level of experimental noise). This experimental validation
step is important because it corrects for any deviations from
the theoretically optimal measurement conditions that
underlie the computational simulation of measurement val-
ues.
When the optimization and validation steps are completed
and the user is satisfied with the overall performance, one or
more candidate biomarkers are typically selected for further
development. MethMarker provides two ways of facilitating
the steps toward comprehensive clinical testing and wide-
spread practical use. First, MethMarker can generate a com-
prehensive PDF report describing the key properties of a
selected biomarker. This report includes the final sample
classification formula as well as a summary of the accuracy
and robustness assessment. Based on this file, it is straight-
forward to apply the biomarker assay to new data, requiring
no statistical or bioinformatic tools beyond a pocket calcula-
tor. Second, a selected biomarker can be exported in a stand-
ardized data format, PMML, which is supported by several
statistics packages and can be imported into diagnostics soft-
ware. PMML has been developed by the Data Mining Group
[23] to facilitate data exchange between developers and users
of classification and regression models. All classifiers created
with MethMarker fulfill the PMML 3.2 standard (see Addi-
tional data file 2 for illustration). Third, MethMarker sup-
ports multi-center biomarker validation studies. To that end,
the PDF and PMML documentation files of the selected
biomarker are distributed to all participating centers; each
center then performs the necessary DNA methylation assays
for all local samples, loads the PMML file and the measure-
ment values into MethMarker and obtains the biomarker
result for each of their samples; finally, the measurement val-
ues from all centers as well as the corresponding clinical data
are combined, loaded into MethMarker and a global assess-
ment of biomarker performance is obtained. If the perform-http://genomebiology.com/2009/10/10/R105 Genome Biology 2009,     Volume 10, Issue 10, Article R105       Schüffler et al. R105.9
Genome Biology 2009, 10:R105
ance is not satisfactory, the entire process can be reiterated
and the biomarker re-optimized based on the data obtained in
the previous round of validations.
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